Navigation Links
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions
Date:5/25/2011

mer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen's business.  Unless otherwise noted, Amgen is providing this information as of May 25, 2011 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as e
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, ... company, today announced that the Food and Drug Administration ... provide comments on RCP,s Investigational New Drug ("IND") application ... trial in the US. Dr. Chris ... review and comments on our IND. When we receive ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed ... diagnosed incident cases in 2013 to 11,568 diagnosed incident ... of 4.35%, during the forecast period. In 2023, the ... cases of aGVHD in the 6MM, with 4,989 diagnosed ... of diagnosed incident cases of aGVHD, with 704 diagnosed ...
(Date:7/13/2014)... 2014 A decreased ability to identify odors ... Alzheimer,s disease, while examinations of the eye could ... with Alzheimer,s, in the brain, according to the ... the Alzheimer,s Association International Conference 2014 (AAIC 2014) ... the decreased ability to identify odors was significantly ...
(Date:7/13/2014)... Wright & Schulte LLC has learned that ... July of 2015, in U.S. District Court, District of ... discovery process in the South Carolina federal court ... the multidistrict litigation (MDL). The complaints pending in the ... allege that they took the statin medication to lower ...
(Date:7/13/2014)... Celebrity fitness trainer and former World Super ... with Aqua Health Labs for their flagship product PhytOriginal, ... The collaboration was recently announced live on ESPN Radio. ... actor, model, and a two time World Super Middleweight ... has prepared stars including Demi Moore, Hilary Swank and ...
(Date:7/13/2014)... Palatine, Illinois (PRWEB) July 13, 2014 Hope ... facilitating a monthly grief support group at the Tamarack Senior ... will be held at 10:30 A.M. on the 3rd Wednesdays ... July 16th, 2014 at the Tamarack Community located at 55 ... to all bereaved individuals and there is no cost for ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... known that HIV patients are at an increased risk of ... shows // aggressive antiretroviral therapy may help lower that risk. ... therapy was associated with a lower incidence of Kaposi sarcoma ... more than 7,300 patients infected with HIV and the data ...
... In a study published in Diabetes Care, March 2005, scientists ... ,Insulin sensitivity is the measure for the risk ... then he has a lower risk of heart problems. ... insulin to control blood sugar. As this happens the body ...
... and heart attack can be reduced for heart patients undergoing ... of an anti-clotting drug before the procedure is the answer.// ... catheter is threaded into an artery. The balloon is inflated ... A small synthetic tube - stent is used to hold ...
... is known to help in controlling obesity. A new study ... Obesity (2005) says that dietary calcium present in the yogurt ... in lipid utilization and decrease in lipogenesis. ... one group was put on balanced deficit diets and the ...
... standard treatment with levodopa can reduce the amount of ... fluctuations they experience during the day . ,For ... drug entacapone, which must be taken with every levodopa ... of the additional drugs were effective in reducing the ...
... being hailed by researchers for its ability to target cancer ... called ON01910 works by interfering with a molecule known as ... multiply. This molecule is found in higher numbers in cancerous ... have especially high amounts. ,The drug was tested ...
Cached Medicine News:
The Uromac Petite data processor, transducers and Powerbook® computer can be disassembled quickly and easily for travel to multiple sites, providing a very flexible and portable urodynamics syste...
... by Laborie, a leading producer ... credible tracings. ICS recognized Urodynamics ... parameters. Designed especially for the ... to be quick, efficient and ...
... The wireless TRITON™ offers ultimate flexibility ... of the computer, printer and display. Wall-mount ... wireless system by choosing a laptop, touch ... Incorporating the latest technology, this multi-function patient ...
... Advanced diagnostic capabilities combined with ease of ... product in its class. Ideal for office ... complete system for Uroflowmetry, cystometry, leak point ... configurations are available which make the OM-5 ...
Medicine Products: